Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma

被引:27
作者
Ito, Y
Kawakatsu, H
Takeda, T
Tani, N
Kawaguchi, N
Noguchi, S
Sakai, T
Matsuura, N
机构
[1] Osaka Univ, Sch Allied Hlth Sci, Dept Pathol, Fac Med, Suita, Osaka 5650871, Japan
[2] Osaka Seamens Insurance Hosp, Dept Surg, Osaka, Japan
[3] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA
[4] Osaka Univ, Sch Med, Dept Surg Oncol, Osaka, Japan
[5] Lund Univ, Dept Expt Pathol, Lund, Sweden
关键词
breast carcinoma; immunohistochemistry; src;
D O I
10.1023/A:1020860221099
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
In order to investigate whether c-Src is involved in carcinogenesis and progression of breast carcinoma, we examined the expression of activated c-Src in tissue sections from surgically resected human breast specimens. First, we confirmed the specificity of the antibody against activated c-Src (Clone 28) using six cell lines established from human breast carcinomas by western blotting. As expected, activated c-Src was detected as a 60 kDa band in all cell lines tested. Immunofluorescence analysis demonstrated that the activated c-Src was mainly observed in cytoplasms of these cells. Then, we designed an immunohistochemical study with 73 human breast carcinoma tissues. Glandular epithelial and myoepithelial cells in normal mammary glands adjacent to carcinoma nests and infiltrating stromal cells were negative for activated c-Src. In contrast, 37 of the 73 breast carcinoma tested (50.7%) were positive for activated c-Src, and this positive staining was inversely correlated with Ki-67 labeling index (p <0.0001), TNM stage (p <0.0001), tumor size (p < 0.0001), and histological grade (p = 0.0002). These results strongly suggest that the activation of c-Src would be related to the progression of breast carcinomas with low aggressiveness.
引用
收藏
页码:261 / 267
页数:7
相关论文
共 40 条
[1]
P53 AND C-ERBB-2 PROTEIN EXPRESSION IN BREAST CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY INCLUDING CORRELATIONS WITH RECEPTOR STATUS, PROLIFERATION MARKERS, AND CLINICAL STAGE IN HUMAN BREAST-CANCER [J].
BARBARESCHI, M ;
LEONARDI, E ;
MAURI, FA ;
SERIO, G ;
PALMA, PD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (04) :408-418
[2]
INCREASED PP60C-SRC TYROSYL KINASE-ACTIVITY IN HUMAN NEUROBLASTOMAS IS ASSOCIATED WITH AMINO-TERMINAL TYROSINE PHOSPHORYLATION OF THE SRC GENE-PRODUCT [J].
BOLEN, JB ;
ROSEN, N ;
ISRAEL, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (21) :7275-7279
[3]
ACTIVATION OF PP60C-SRC PROTEIN-KINASE ACTIVITY IN HUMAN-COLON CARCINOMA [J].
BOLEN, JB ;
VEILLETTE, A ;
SCHWARTZ, AM ;
DESEAU, V ;
ROSEN, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) :2251-2255
[4]
ACTIVATION OF THE PP60C-SRC PROTEIN-KINASE IS AN EARLY EVENT IN COLONIC CARCINOGENESIS [J].
CARTWRIGHT, CA ;
MEISLER, AI ;
ECKHART, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (02) :558-562
[5]
COLTRERA MD, 1995, CANCER RES, V55, P2703
[6]
DEPHOSPHORYLATION OR ANTIBODY-BINDING TO THE CARBOXY TERMINUS STIMULATES PP60C-SRC [J].
COOPER, JA ;
KING, CS .
MOLECULAR AND CELLULAR BIOLOGY, 1986, 6 (12) :4467-4477
[7]
ACTIVATION OF SRC FAMILY KINASES BY COLONY STIMULATING FACTOR-I, AND THEIR ASSOCIATION WITH ITS RECEPTOR [J].
COURTNEIDGE, SA ;
DHAND, R ;
PILAT, D ;
TWAMLEY, GM ;
WATERFIELD, MD ;
ROUSSEL, MF .
EMBO JOURNAL, 1993, 12 (03) :943-950
[8]
A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[9]
Recognition of activated CSF-1 receptor in breast carcinomas by a tyrosine 723 phosphospecific antibody [J].
Flick, MB ;
Sapi, E ;
Perrotta, PL ;
Maher, MG ;
Halaban, R ;
Carter, D ;
Kacinski, BM .
ONCOGENE, 1997, 14 (21) :2553-2561
[10]
C-ERBB-2 ONCOGENE PRODUCT EXPRESSION DEPENDS ON TUMOR TYPE AND IS RELATED TO ESTROGEN-RECEPTOR AND LYMPH-NODE STATUS IN HUMAN BREAST-CARCINOMA [J].
HEATLEY, M ;
MAXWELL, P ;
WHITESIDE, C ;
TONER, PG .
PATHOLOGY RESEARCH AND PRACTICE, 1993, 189 (03) :261-266